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Purpose: Platelet-activating factor (PAF) is a potent phospholipid mediator of the 
microvascular dysfimction associated with ischemia-reperfusion injury. Because changes 
in cytosolic-free Ca 2 + concentration are essential in PAF ceUular signaling, we formulated 
the hypothesis that blockade of Ca 2+ entry may inhibit the PAF-induced microvascular 
dysfuncdon. 
2Vlethods: To investigate his hypothesis two L-type calcium channel blockers, verapamil and 
nifedipine, were applied to the hamster cheek pouch before the topical PAF challenge was 
undertaken. Permeability was assessed by measurement of the plasma clearance of 
fluorescein sothiocyanate d xtran, 150,000 mol wt. The arteriolar diameter was measured 
simultaneously to evaluate the effects of L-type calcium channel blockers on PAF-induced 
vasoconstriction. 
Results: Baseline dearance was 498.7 -+ 225.0 nl/60 min/gm (mean + SE). PAF at 10 -s 
mol/L (n = 5) increased clearance to 3753.8 + 572.8 nl/60 min/gm (p < 0.01). Pre- 
treatment with verapamil (2 mg/kg; n = 5) significantly reduced the increase in 
permeability caused by 10 -s mol/L PAF (1909.1 + 620.2 nl/60 min/gm; p < 0.05). 
Nifedipine (5 - 10-6 mol/L; n = 5 ) also significantly attenuated the impact of 10- s mol/L 
PAF (2037.2-+ 427.5 111/60 min/gm; p < 0.05). Neither verapamil nor nifedipine 
affected PAF-induced vasoconstriction. 
Conclusion: The significant inhibition of the increase in permeability by the L-type calcium 
channel blockers suggests that these compounds may be useful in the management of
PAF-induced hyperpermeability. (J VASC SURG 1995;22:732-41.) 
Platelet-activating factor (1-O-alkyl-2-O-acetyl- 
sn-3-phosphorylcholine; PAF) is apotent phospho- 
lipid mediator involved in a variety of inflammatory 
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and allergic reactions, including anaphylaxis, endo- 
toxin shock, gastrointestinal ulceration, and is- 
chemia-reperfusion (IR). 13 PAF is produced in 
response to hypoxia and increases adherence proper- 
ties of cultured porcine aortic endothelial cells 4 and 
human umbilical vein endothelial cells, s In vivo, PAF 
induces macromolecular leakage and arteriolar con- 
striction and adhesion of leukocytes 68 and.mediates 
leukocyte--endothelial cell interactions in IR. 9-~~ 
These data suggest that PAF plays an important role 
in the pathogenesis of IR injury. 
PAF is activated by way of multiple signaling 
pathways through specific receptors on the plasma 
membrane.l,i2,13 These signaling mechanisms lead to 
an increase in cytosolic-free Ca 2+ concentration 
([Ca2+]i) resulting both from intracellular Ca 2+ 
release mediated by inositol 1,4,5-triphosphate 
(IPs) through phospholipase C (PLC) activation and 
from Ca 2+ influx. 2'12 However, the in vivo actions of 
PAF-induced Ca 2+ entry into cells have not been 
elucidated entirely. In this study we investigated the 
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Fig. 1. Diagram of experimental protocols. Verapamil (2 mg/kg) was administered intrave- 
nously over 10-minute period. PAF challenge was instituted 10 minutes after stopping 
application of verapamil. Thus 20-minute period refers only to sum of time of administration 
of verapamil plus time allowed for recovery of blood pressure. Nifedipine at 10 -7 mol/L or 
5 × 10- mol/L was applied topically to hamster cheek pouch for 10 minutes. PAF challenge 
was implemented immediately after application of nifedipine. 
effect of calcium channel blockers on the hamster 
cheek pouch as an in vivo experimental model for 
the role of calcium entry in the microvascular 
changes induced by PAF. We applied two L-type 
voltage-operated channel blockers-verapamil (phe- 
nylalkylamine) and nifcdipine (a 1,4-dihydropyr- 
idine [DHP] derivative)-to evaluate the effect 
of PAF-induced calcium entry on microvascular 
function. 
MATERIAL AND METHODS 
Animal preparation. Thirty-seven male golden 
Syrian hamsters (weighing 80 to 120 gin) were 
anesthetized with sodium pentobarbital (60 mg/kg, 
administered intraperitoneally). Tracheotomy was 
performed to ensure clear airway passages. The 
animal was placed on a heating pad to keep the body 
temperature at 37 ° C throughout the experiment. 
The right jugular rein was cannulated for the 
administration of supplemental doses of anesthetic, 
macromolecular t acer, and verapamil. The right 
carotid artery was cannulated for collection of blood 
samples and for monitoring of systemic blood 
pressure. The left hamster cheek pouch was prepared 
for intravital microscopic observation and interven- 
tion as described previously. 7,14 Briefly, the cheek 
pouch was carefuUy exposed by removal of the 
connective tissue. A two-piece acrylic resin chamber 
(1 ml of reservoir capacity) was attached to the cheek 
pouch. The cheek pouch was continuously super- 
fused with bicarbonate buffer solution (NaC1, 131.9 
mmol/L; KC1, 4.7 mmol/L; CaCI2, 2 mmol/L; 
MgSO4, 1.2 mmol/L; and NaHCO» 18 mmol/L) at 
a rate of 1 ml/min. The buffer solution was adjusted 
to pH 7.35, warmed to 35 ° C, and equilibrated with 
95% nitrogen/5% carbon dioxide. The cheek pouch 
preparation was allowed to stabilize for a 1-hour 
period before any control measurements were per- 
formed. 
Experimental protocols. The protocols are 
illustrated in Fig. 1. The direct effects of the vehicle 
on the microvascular network, if any, were tested in
three animals for the entire duration of the experi- 
mental protocols. In agreement with out previous 
experience, the vehicle had no effect on microvascular 
dynamics. 6,7 After the baseline data were collected, 
PAF at 10 -8 mol/L (n = 5), or 10 "7 mol/L (n = 6), 
was topically applied to the cheek pouch for 3 
minutes by means of temporary interruption of the 
superfusate flow. Each animal received only one dose 
of PAF. After PAF challenge, the superfusate flow 
was reestablished and the effluent was collected at 
5-minute intervals for 1 hour. In nine animals, 
verapamil (2 mg/kg) was applied intravenously over 
JOURNAL OF VASCULAR SURGERY 
734 Oshiro et al. December 1995 
fr) 
13.. 
O 
O 
133 
140- 
120 
100 
80 ¸  
60- 
40- 
0~ 
verapamil .---~, 
PAF 
I I I I I 
0 5 10 15 20 25 
Time (min) 
Fig. 2. Effcct ofverapamil (2 mg/kg administered intravenously) on systemic blood pressure. 
Ordinate shows percent change in blood pressure normalized to control. Blood pressure 
remrned to 100% of control within 10 minutes. Data are presented as mean _+ SE (n = 4). 
10 minutes. Because this dose of verapamil caused 
approximately 15% decrease in systemic blood pres- 
sure during its application, PAF ehallenge was 
instituted on return to baseline values of systemic 
blood pressure. Blood pressure returned to baseline 
values usually 10 minutes after stopping the applica- 
tion of verapamil (Fig. 2, n = 4). In 10 animals, 
nifedipine at 10 -7 mol/L (n = 5) or 5 x 10 .6 
mol/L (n = 5) was applied topically for 10 minutes. 
These doses of nifedipine did not affect systemic 
blood pressure. PAF challenge at 10 -8 mol/L was 
implemented after the nifedipine application. 
Microvascular permeability. We used fluo- 
rescein isothiocyanate-dextran 150,000 mol wt 
(FITC-Dx 150) as a macromolecular t acer for 
microvascular permeability. FITC-Dx 150 was ad- 
ministered intravenously as a 100 mg/kg bolus 45 
minutes into the stabilization period and followed by 
continuous infusion (0.15 mg/kg/min) to maintain a
constant plasma concentration. Superfusate (5- 
minute collection samples) and plasma concentra- 
tions of FITC-Dx 150 were determined by use of a 
Perkin-Elmer LS-3 spectrofluorometer (Perkin- 
Eimer, Norwalk, Conn.). Microvascular plasma 
clearance was determined from the following 
formula: Clearance value (N/min/g) = (Superfusate 
concentration fFITC-Dx 150 [ng/ml] x Flow rate 
[ml/min])/(Plasma concentration of FITC-Dx 150 
(mg/ml) x Pouch weight). Cumulative clearance 
values for the complete baseline and experimental 
periods were computed by simple addition of the 
5-minute clearance values. 
Arteriolar diameter measurement. We mea- 
sured arteriolar luminal diameter as the width of the 
transilluminated blood column. Three to five arteri- 
oles (20 to 40 txm in diameter) per animal were 
studie& The selected vessels were video recorded 
during the control period and at 2-minute intervals 
for 10 minutes after the application of PAF. Control 
diameters were normalized to a value of one, and the 
experimental diameter was expressed as a ratio of the 
control diameter (experimental/control = relative 
luminal diameter). Because topical application of 
nifedipine caused vasodilation, the arteriolar diam- 
eter measured at the end of the administration of 
nifedipine was used as the bascline to cvaluate the 
effect of subsequent PAF-induced vasoconstriction. 
Chemicals. All chemicals were obtained from 
Sigma Chemical Co., St. Louis, Mo. PAF was 
initially dissolved in dimethyl sulfoxide (DMSO) to 
a concentration of 10 -2 mol/L and was diluted 
subsequently to the desired concentrations with a 
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Fig. 4. Statistical analysis of effect of nifedipine on PAF-induced increase in FITC-Dx 150 
clearance. Data are presented as mean -+ SE. Numbers in parentheses show number of animals. 
"i0 < 0.05 compared with 10 -s mol/L PAF. 
mixture of  1.5% bovine serum albumin and bicar- 
bonate buffer. Verapamil was dissolved and diluted 
with saline solution before application. Nifedipine 
was dissolved in DMSO to 10 -1 mol/L and was 
diluted with bicarbonate buffer. The final concentra- 
tion of DMSO was less than 0.1% and did not affect 
microvascular parameters. 
Statistieal analysis. All data are expressed as 
means _+ SE. Date were analyzed by use ofunpaired 
t testing and one-way analysis of variance testing 
followed by Student-Newman-Keuls' multiple range 
testing. Thep values less than 0.05 were considered 
significant. 
RESULTS 
Initially, both verapamil and nifedipine were 
dcsigned to be applied topically to the hamster 
cheek pouch. In preliminary experiments, however, 
topical application of  verapamil at 10 -s mol/L 
causcd a significant increase in HTC-Dx 150 clear- 
ance (data not shown). Therefore verapamil at 2 
mg/kg was applied intravenously. This dose of 
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Fig. 5. Effect of verapamil on PAF-induced arteriolar vasoconstriction. Arteriolar diameters 
were measured during control period and at 2-minute intervals after application ofPAF. Control 
diameters were normalized to value of one, and experimental diameters are presented as ratio 
of control diameter (experimental/control = relative luminal diameter). Numbers in parentheses 
show number of animals. Data are presented as mean -+ SE. 
verapamil is efficacious in attenuating macromo- 
lecular leakage in IR. z~ Neither intravenous appli- 
cation of verapamil nor topical application of ni- 
fedipine caused significant increase in FITC-Dx 150 
compared with control. 
Permeability 
Previous studies in our laboratory have estab- 
lished that PAF at 10 -7 mol/L causes maximal 
increase in FITC-Dx 150 clearance in the hamster 
cheek pouch. 7 In this study we initially chose 10 -7 
PAF (n = 6) as the test concentration. We found out 
experimentally that the effects of this maximal 
concentration f PAF were not attenuated byverap- 
amil, possibly as a result of stoichiometric relations 
between agonist and antagonist. Therefore we chose 
to use PAF at 10 -8 mol/L (n = 5) as the test 
challenge and applied only this dose to the study 
of the effects of nifedipine. Both 10 _8 mol/L and 
10 7 mol/L PAF caused significant increase in 
FITC-Dx 150 clearance compared with vehicle 
(3841.6 + 260.9 and 4747.7 + 584.3 vs 498.7 + 
225.3 nl/ö0 min/gin, respectively; p < 0.01) 
(Fig. 3). 
Verapamil. Fig. 3 shows that pretreatment with 
verapamil significanfly attenuated the increase in 
FITC-Dx 150 clearance induced by 10 -s mol/L PAF 
(1909.1 -- 620.2 nl/ó0 min/gin, p < 0.05). The 
permeability increase induced by 10 7 molfL PAF 
was not attenuated by intravenously administered 
verapamil (5171.7 -+ 1238.1 nl/ó0 min/gin). 
Nifedipine. Topical pretreatment with nifedi- 
pine attenuated the increase in FITC-Dx 150 clear- 
ance induced by 10 -8 mol/L PAF in a dose- 
dependent manner. Nifedipine at 5 x 10 -6 mol/L 
significantly reduced the increase in clearance induced 
by PAF at 10 -8 mol/L (2037.2 m 427.5 111/60 
min/gin, p < 0.05). Nifedipine at 10 -7 mol/L also 
attenuated the 10-s mol/L PAF-induced permeabil- 
ity change (2945.3 + 437.3 nl/ó0 min/gm). Nifed- 
ipine at 10 -7 mol/L may represent a near-threshold 
concentration because the reducfion in clearance was 
not significantly different compared with 10-8 mol/L 
PAF (Fig. 4). 
Arteriolar diameter 
Topical application of PAF at 10 -8 mol/L or 
10-7 mol/L caused maximal vasoconstricfion within 
2 minutes after PAF application (relative luminal 
diameter ratios 0.69 _+ 0.04 and 0.45 _+ 0.03, re- 
spectively). Thereafter, arteriolar diameter gradually 
returned toward the baseline in the 10-minute 
observation period. 
Verapamil. Pretreatment with verapamil did not 
attenuate the maximal arteriolar constriction at 2 
minutes after the application ofeither 10-8 mol/L or 
10 7 mol/L PAF (0.62 +_ 0.10 vs 0.69 +_ 0.04 and 
0.43 + 0.03 vs 0.45 _+ 0.03, respectively). Verap- 
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Fig. 6. Effect ofnifedipine on l0 -8 mol/L PAF-induced vasoconstriction. Arteriolar diameters 
were measured during control period and at 2-minute intervals after application of PAF. Control 
diameters were normalized to value of one, and experimental diameters are presented as ratio 
of control diameter (experimental/control = relative luminal diameter). Numbers in parentheses 
show number of animals. Data are presented as mean _+ SE. 
amil pretreatment had no significant effect on the 
PAF-induced arteriolar constriction (Fig. 5). 
Nifedipine. Nifedipine, at either [[0 .7 mol/L 
or 5 × 10 6 mol/L, did not reduce the vasocon- 
striction occurring at 2 minutes after l0 -8 mol/L 
PAF challenge (0.57 +_ 0.07 and 0.73 _+ 0.08 vs 
0.69 _+ 0.04, respectively). Nifedipine had no signif- 
icant effect on the vasoconstriction induced by 10 8 
mol/L PAl: (Fig. 6). 
DISCUSSION 
This study demonstrates that pretreatment with 
two L-type calcium channel blockers, verapamil and 
nifedipine, significantly attenuated the increase in 
FITC-Dx 150 clearance induced by PAF. Neither of 
the calcium channel blockers affected the PAF- 
elicited arteriolar constriction. 
Attenuation of PAF-indueed hyperpermeabil- 
ity by verapamil and nifedipine. In general, the 
mechanism of increasing macromolecular permeabil- 
ity induced by PAF has been considered to be the 
result of a wider intercellular gap as a consequence of
endothelial cell contraction.16 PAF causes areversible 
change of endothelial cell shape and an increase of 
albumin transfer across endothelial cell monolayers.17 
Along with [Ca2+]i ncreases, actin and myosin may 
play a central role in the regulation of the width of 
endothelial intercellular gaps. 18 In in vitro studies, 
PAF induces a rapid increase of [Ca2+]i n cultured 
endothelial cells. 19,20 Furthermore, both PAF synthe- 
sis and rapid endothelial cell-dependent polymor- 
phonuclear leukocytes adhesion require Ca 2 + .21 Thus 
an elevation in [Ca2+]i seems to be one of the initial 
important events in the cellular signaling cascade 
associated with stimulation by PAF, as well as other 
mediators of inflammation. 
At least two mechanisms are involved in PAF- 
induced lea 2+ ]i increase. One is Ca 2 + influx into the 
cytoplasm and the other is mobilization of Ca 2+ from 
intracellular stores in response to elevated IP 3 
through activation of the PLC pathway. 2,I2 Of  the 
total increase of [Ca2+]i caused by PAF, about one 
fourth is due to the IPa-induced mobilization of 
Ca 2 +.12 Thus PAF-induced [Ca 2 + ]i elevation appears 
to be predominantly due to Ca ~+ influx; however, the 
precise pathways through which Ca 2+ enters into the 
cytoplasm have not been completely elucidated yet. 
In platelets, receptor-operated channels have been 
proposed as a Ca 2 + entry stimulated by PAF, because 
voltage-operated channels do not exist in platelets. 22 
Recently, direct measurements of Ca 2+ channel 
current and [Ca2+]i have been achieved by use of 
both patch clamp techniques and fluorochrome- 
preloaded cells. In cultured endothelial ceils, experi- 
mental electrophysiologic evidence indicates alack of 
functional voltage-operated Ca 2+ channels; however, 
there are concerns about the technical difficulties 
involved in measuring small Ca 2 + currents, the loss of 
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Ca 2+ channels during enzymatic digestion, lack of 
expression of Ca 2 ÷ channels, and lack of sensitivity to 
the normal Ca 2+ channel agonists and antagonists 
under the experimental conditions. 23 Nonetheless, 
with fura-2-preloaded vascular endothelial cells, a 
new voltage-operated calcium channel (R-type) has 
been reported in vascular endothelial cells. 24 This 
R-type channel may play a role in the PAF-elicited 
cellular signaling events. 24 
Our smdy shows that blockade of L-type calcium 
channel inhibits the pathways of PAF cellular signal- 
ing in vivo. However, we cannot attribute this 
property uniquely to a change in the activity of 
voltage-operated Ca 2+ channels in endothelial cells. 
Verapamil inhibits the PAF-elicited responses in 
platelets 2 and neutrophils 26 by mechanisms other 
than inhibition of Ca 2+ influx. In vitro data suggest 
that PAF receptors are closely linked to Ca » 
channels in the plasma membrane. 13,26 This observa- 
tion is in agreement with the report hat specific DHP 
derivatives are novel PAF-receptor antagonists. 27The 
assumed mechanism of action of calcium channel 
blockers is their binding to a site associated with the 
PAF receptor-linked channel. 27 
Thus verapamil and nifedipine are likely to 
modulate the hyperpermeability induced by PAF 
possibly through inhibition of both Ca 2+ entry and 
PAF-receptors. Because neither Ca 2+ entry antago- 
nist could completely abolish the PAF-induced per- 
meability increase, we postulate that there are other 
signaling pathways, including PAF-receptors and 
other  Ca 2+ channels, that participate in the PAF- 
induced hyperpermeability. 
We did not measure leukocyte adhesion to 
venular endothelium in this study because of logistic 
reasons. It is unclear whether leukocytes play a role in 
the PAF-induced hyperpermeability under out ex- 
perimental conditions. Although some leukocyte 
adhesion is possibly elicited by 10 _8 mol/L PAF, 
maximal leukocyte adhesion is stimulated by PAF at 
10 -9 and 10 -11 mol/L. 8 It is worth noting that PAF 
does not stimulate hyperpermeability at these low 
concentrations. 28 If pretreatment with calcium entry 
channel blockers leads to priming interactions be- 
tween PAF and other endogenous agonist, then a 
more predominant role for leukocytes i  possible. We 
have demonstrated previously that polymorpho- 
nuclear leukocytes are involved in mediating the 
microvascular hyperpermeability caused by priming 
interactions between PAF and histamine. 29 
L-Type calcium channel blockers and PAF- 
induced arteriolar vasoconstriction. PAF-induced 
arteriolar constriction in the hamster cheek pouch is 
mediated by thromboxane A2, 6'28 which is generated 
through phospholipase A 2 activation. In general, 
within 5 to 10 seconds ofPAF challenge, the level of 
IP 3 increases everalfold, resulting in an increase in 
[ Ca2 + ]i.12 Direct measurement of [Ca 2 + ]i in culmred 
bovine aortic endothelial cells revealed that 10 -7 
mol/L PAF caused a transient increase of [Ca2+]i , 
which reached a maximum value within 30 to 60 
seconds and subsequenfly returned to control evels 
within 9 minutes. 19 The general pattern of the time 
course of [Ca2+]i movement seems compatible with 
that of the PAF-induced arteriolar constriction ob- 
served in this study. Generally, application of PAF (at 
concentrations of 10 -8 mol/L and higher) to the 
hamster cheek pouch canses a peak constriction, in a 
dose-related manner, within the first 2 minutes, 
which subsequently remrns gradually to the base line 
in about 10 minutes. 6 
The failure ofverapamil and nifedipine to inhibit 
the PAF-induced vasoconstriction may be due to the 
following reasons: (1) neither verapamil not nifedi- 
pine inhibits phospholipase A 2 activation, and thus 
do not prevent he production of thromboxane A2; 
(2) neither agent prevents the release of Ca 2+ from 
intracellular stores through the PLC pathway; (3) 
either agent may only partially inhibit Ca 2+ influx; 
and (4) assuming that verapamil and nifedipine block 
PAF-receptors, there may be a difference between the 
PAF receptors present in arterioles and the PAF 
receptors present in postcapillary venules. 3° 
We conclude that t-type calcium blockers may be 
useful in the management ofPAF-induced hyperper- 
meability hut not its associated vasoconstriction. Our 
data suggest hat calcium channel blockade may at 
least partially protect he microcirculation i  disease. 
Furthermore, PAF-receptor blockade may provide a 
mechanism for controUing microvascular dysfunc- 
tion in IR injury. 11 
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DISCUSSION 
Dr. Thomas F. Panetta (Brooklyn, N.Y.). Dr. Oshiro 
et al. have provided data that L-type calcium channel 
blockers can reduce the capillary leak of macrornolecules 
induced by the topical administration of PAF. However, 
these calcium channel blockers had no effect on PAF- 
induced vasoconstriction. There was an eightfold increase 
in microvascular permeability as a resuk of the topical 
application of PAF to the hamster cheek pouch. Pretreat- 
ment with topical nifedipine or intravenous verapamil 
resulted in a 50% decrease in the capillary leak that still 
remained a fourfold increase over baseline permeability. 
The Newark group has previously demonstrated a similar 
effect ofverapamil in the ischemic model with rat cremaster 
muscle. However, in the cremaster muscle model of IR, 
verapamil maintained the microvascular integrity to near 
baseline levels. 
Why is there an incomplete response to 1-type calcium 
channel blockers in the hamster cheek pouch and a 
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near-complete r sponse in IR in cremaster muscle? Is this 
related to differences between topical PAF administration 
and true IR injury, or is this a function of differences 
between calcium channel activity in the gracilis muscle 
versus the hamster cheek pouch? PAF increases intracellular 
calcium in human and canine endothelial cells, which is not 
prevented by nifedipine. This response has been demon- 
strated to be due primarily to R-type calcium channels. Can 
you speculate on the role of variable responses and the 
variety of calcium channels including nonspecific ation 
channels in the sodium-calcium exchanger in both species 
variations and experimental differences in your t~ndings? 
Why does topical verapamil increase macromolecule 
permeability whereas intravenous administration does not? 
Although this is an incidental tinding that was provided in 
the manuscript, does this provide any insight into the role 
of endothelial cells in these interactive cellular processes? 
Likewise, do differences in results between vasoreactivity 
and capillary leak reflect a different mechanism or possibly 
an intact endothelial cell layer interposed between reactive 
smooth muscle cells at the time of pretreatment? 
With ischemia, phospholipase A2 (PLA2) activity 
initiates the membrane r lease of PAF and arachidonic acid, 
the precursor of eicosanoids, including thromboxane. 
Concomitant phospholipase C activation stimulates the 
inositol pathways to release intracellular calcium stores, 
which, in combination with protein kinase C activity, 
opens calcium channels for calcium influx. Capillary leaks, 
on the other hand, occur relatively late in the cascade and 
are associated more with reperfusion events that activate 
cyclooxygenase and lipoxygenase pathways and release free 
radicals. 
Keeping in mind that topical application of PAF is 
different than an IR model, where does PAF-induced 
microvascular dysfunction fit into this cascade? Does 
activation ofPAF receptors directly increase phospholipase 
C activity, or are there changes mediated by PAF-induced 
increase in eicosanoids, free radicals, or cytokines? Do you 
think that PAF receptor antagonists might completely 
abolish the permeäbility changes caused by exogenous 
PAF? Are you considering experiments with PAF antago- 
nists and, additionally, with deacylated PAF or lyso-PAF or 
other PAF analogs to confirm that your findings are both 
PAF and PAF receptor specific? 
In the manuscript there is no mention of intracellular 
receptors that exist for PAF. I have some concerns that, 
although topical application of PAF is an excellent means 
of elucidating some of these complicated biochemical 
interactions, this model does not result in intracellular 
increases in PAF, which could potentially initiate alterna- 
tive cell signaling systems, including second messenger and 
third messenger cell signaling pathways. Would you 
comment? 
What is the clinical relevance of these findings? 
Considering the findings, do l-type calcium channel block- 
ers have a role in treating IR disorders or might they be 
more useful in conditions with severe capillary leaks such as 
bums, septic shock, or adult respiratory distress yndrome? 
Dr. Hidemi Oshiro. To answer your first and third 
questions, I want to review briefly the PAF-induced 
signaling pathways. PAF operates through specific recep- 
tors on the plasma membrane. These receptors activate 
phospholipases Ag, C, and D (PLC, PLD), as well as 
calcium channels. Stimulation of PLC and PLD leads to the 
activation of protein kinase C (PKC) and of calcium 
mobilization from intracellular stores (via inositol trispho- 
sphate). Our laboratory has reported that activation of 
PKC increases microvascular permeability to macromol- 
ecules (AmJPhysiol 1994;26ö:H1214-20). The activation 
of PKC may be independent of the action of PAF on 
calcium entry via calcium channels, which is believed to be 
the predominant route for calcium-related increases in 
microvascular permeability. Thus blockade of L-type and 
R-type calcium channels would be expected to effect only 
a partial block of the PAF-induced enhäncement of 
microvascular permeability. 
Our laboratory has also demonstrated that PAF- 
induced vasoconstriction is mediated by thromboxane A 2. 
Again, this PLA2-mediated pathway does not depend 
entirely on calcium entry and explains the maintenance of
the PAF-vasoconstrictor effect in the presence ofnifedipine 
and verapamil. 
Where does PAF-induced microvascular dysfunction fit 
in the biochemical cascade? The sequence of hypoxia and 
reoxygenation causes an increase in PAF release in endo- 
thelial cells, so there is some in vitro evidence for the 
production of PAF m~der conditions that mimic IR (AmJ 
Pbysiol 1992;263:H956-62). As indicated, we have dem- 
onstrated in out in vivo preparation that PAF triggers a 
well-defined biochemical pathway resulting in increased 
microvascular permeability. As PAF stimulates PLA2, PLC 
and PLD, a constellation of prohyperpermeability factors 
are set in motion, including calcium mobilization, leuko- 
trienes, nitric oxide, and cytoldnes. 
Precapillary and postcapillary effects of PAF are medi- 
ated by different receptors (AmJPhysio11991;261:H1648- 
52) and potentially different biochemical signaling path- 
ways (Am J Pbysiol 1994;266:H1214-20). We have re- 
ported that WEB 2086, a universal PAF antagonist, 
effectively blocks the adhesion of leukocytes to postcapil- 
lary venular endothelium in IR (Surg Forum 1992;43:376- 
8). Experiments with lyso-PAF have demonstrated the 
receptor specificity for PAF. 
As indicated earlier, in our in vivo experiments with 
exogenously applied PAF, we have demonstrated the 
PAF-stimulated activation of a biochemical signaling 
pathway that includes PLA2, PLC, PLD, PKC, and NO. 
These findings support he efficacy ofthis experimental tool 
to elucidate the role of specific agonists in the control of 
microvascular funcuon in health and disease. 
Regarding yonr question about the differences be- 
tween models and animal species, in these experiments we 
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used as a challenge a PAF concentration of 10 -8 mol/L, 
which has been reportedly measured in models of IR in the 
intestine ( Biochem Biophys Res Commun 1989;158:353-9). 
It is possible that verapamil might be more efficacious 
under conditions of IR. It is also possible that the 
concentrations of PAF produced in the rat cremaster model 
are lower than 10-a mol/L. It is also known that rats are less 
sensitive to PAF than hamsters. 
Your final question relates to the clinical relevance of 
our findings. The clinical use of verapamil and nifedipine is 
well established inspecific settings. Our results uggest they 
might be useful in the management of IR. However, 
caution must be exercised because these agents limit the 
extent of the change in microvascular permeability, but may 
not be as efficacious in controlling the hemodynamic 
aspects of reperfusion. 
I want to add that PAF-receptor antagonists may 
provide some additional benefit in the treatment of IR 
because they block the adhesion of leukocytes to endothe- 
lium in postischemic tissue. This beneficial action is 
achieved whether the PAF-receptor antagonist is adminis- 
tered before ischemia or just before reperfusion (Surg 
Forum 1992;43:376-8). These results are encouraging for 
further exploration of agents that may assist in the 
postoperative management of vascular diseases. 
Dr. Robert W. Hobson I I  (Newark, N.J.). One of the 
difficulties in carrying out basic research is to translate the 
results into our clinical practice. To answer Dr. Panetta's 
question regarding clinical relevance of Dr. Oshiro's data, 
we need to define the severity of skeletal muscle injury in 
terms of clear clinical endpoints. These well-defined end- 
points would allow us to compare data from different 
hospitals and clinics and would facilitate the translation of 
basic research into clinical practice. 
Thus I want to reiterate a challenge to all of us to define 
endpoints that will allow us to compare our independent 
surgical results and to conduct prospective randomized 
trials on the pharmacologic manipulation of the IR 
syndrome. 
Dr. Marsel Huribal (Buffalo, N.Y.). Use of nitric 
oxide inhibitor had similar results on your model and 
PAF-induced microvessel leakage. How do PAF and nitric 
oxide interregulate? 
During ischemia there is a significant amount of 
endothelial cell dysfunction in which there is a significant 
amount of vasoactive substances that are produced, of 
which endothelin isat least 100,000-fold more potent han 
PAF in vasoconstriction a d leukocyte activation and free 
radical production; it also enhances capillary leakage" in 
itself and goes through several calcium mechanisms a  you 
described. I believe ndothelin also induces PAl; activation. 
With this in mind, although you have a lot of potent 
vasoactive substances, how important isPAF or nitric oxide 
in ischemia or reperfusion i jury? 
Some patients who are receiving calcium channel 
blockers till have development ofreperfusion i jury. What 
is the role of l-type calcium signaling in the clinical 
situation? 
Dr. Oshiro. We have in vivo evidence demonstrating 
that the mechanism of PAF-induced increase in permeabil- 
ity involves a stimulated biochemical signaling pathway 
that includes enhanced activity of nitric oxide synthase 
(NOS) and increased production of nitric oxide (2dicrovasc 
Res Sept/Oct. 1995;50:223-34). Our experiments are con- 
sistent with the activation of the constitutive form of NOS. 
We have experimental evidence that NOS activity is 
elevated after activation of PKC. The experiments reported 
by Dr. Noel investigate the priming interactions between 
PAF and histamine. Dr. Noel's studies demonstrated that 
NO is a factor involved in the priming interactions leading 
to an increase in microvascular permeability o macromol- 
ecules. Whether NO is stimulated by PKC under priming 
conditions remains to be elucidated. 
Endothelins are agents that produce vasopressor re- 
sponses in whole animals and vasoconstriction in perfused 
vessels in the range of 10 -9 mol/L. At lower concentra- 
tions, endothelins tend to produce vasodilation. The 
vasopressor responses to endothelins are concentration a d 
receptor-type d pendent. Interestingly and somewhat para- 
doxically, removal of endothelin-1 (by molecular biology 
techniques) in mice results in blood pressure higher than 
normal (Nature 1994;368:703-10). PAF is a vasoconstric- 
tor at concentrations of 10 -8 mol/L and 10 -r mol/L, 
whereas at concentrations lower than 10 -9 mol/L, it tends 
to be a vasodilator. We have not yet investigated the 
possible relations between these clearly relevant and 
important molecules. 
